|
Q4 2023
|
16 |
231,228 |
EOLS, ADMA, AMLX, QDEL
|
13F-HR
|
2/13/2024 |
000093583624000133 |
|
Q3 2023
|
23 |
301,032 |
QDEL, EOLS, AMLX, ADMA
|
13F-HR
|
11/13/2023 |
000093583623000688 |
|
Q2 2023
|
2 |
11,032 |
XFOR, DCTH
|
NEW HOLDINGS
|
8/16/2023 |
000093583623000589 |
|
Q2 2023
|
19 |
266,194 |
QDEL, EOLS, ADMA, GLPG
|
13F-HR
|
8/11/2023 |
000093583623000564 |
|
Q1 2023
|
22 |
298,170 |
AMYT, GLPG, CTIC, ADMA
|
13F-HR
|
5/12/2023 |
000093583623000397 |
|
Q4 2022
|
19 |
237,711 |
AMYT, APEN, CTIC, ADMA
|
13F-HR
|
2/14/2023 |
000093583623000233 |
|
Q3 2022
|
19 |
222,441 |
AMYT, QDEL, CTIC, XERS
|
13F-HR
|
11/10/2022 |
000156761922019570 |
|
Q2 2022
|
25 |
214,932 |
AMYT, CTIC, XERS, ADMA
|
13F-HR
|
8/12/2022 |
000156761922015877 |
|
Q1 2022
|
28 |
241,108 |
AMYT, CTIC, XERS, AMRN
|
13F-HR
|
5/16/2022 |
000156761922010659 |
|
Q4 2021
|
23 |
217,913 |
AMYT, CTIC, XERS, ADMA
|
13F-HR
|
2/14/2022 |
000156761922003693 |
|
Q3 2021
|
31 |
219,763 |
AMYT, CTIC, ADMS, GLPG
|
13F-HR
|
11/12/2021 |
000156761921020046 |
|
Q2 2021
|
26 |
191,224 |
AMYT, CHMA, CTIC, ADMS
|
RESTATEMENT
|
8/16/2021 |
000156761921015565 |
|
Q1 2021
|
29 |
185,124 |
AMYT, ADMS, CHMA, CBIO
|
13F-HR
|
5/14/2021 |
000156761921010194 |
|
Q4 2020
|
21 |
130,625 |
LGND, AMYT, DMAC, AYTU
|
13F-HR
|
2/12/2021 |
000156761921003590 |
|
Q3 2020
|
17 |
96,131 |
LGND, ISEE, AMYT, CTIC
|
13F-HR
|
11/13/2020 |
000156761920019541 |
|
Q2 2020
|
13 |
51,630 |
ISEE, LGND, CTIC, DMAC
|
13F-HR
|
8/13/2020 |
000156761920015104 |
|
Q1 2020
|
27 |
94,557 |
LGND, ISEE, CTIC, AMRN
|
13F-HR
|
5/14/2020 |
000156761920010136 |
|
Q4 2019
|
23 |
143,457 |
AMRN, ISEE, AFMD, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
2/13/2020 |
000156761920003323 |
|
Q3 2019
|
26 |
103,032 |
AMRN, OXFORD IMMUNOTEC GLOBAL PLC, BDSI, ENTA
|
13F-HR
|
11/13/2019 |
000156761919021211 |
|
Q2 2019
|
25 |
145,241 |
LGND, VNDA, AMRN, BDSI
|
13F-HR
|
8/13/2019 |
000156761919016550 |
|
Q1 2019
|
30 |
173,855 |
VNDA, AMRN, LGND, NEOS
|
13F-HR
|
5/14/2019 |
000156761919010831 |
|
Q4 2018
|
22 |
113,865 |
AMRN, BDSI, BSTC, CPIX
|
13F-HR
|
2/13/2019 |
000156761919003836 |
|
Q3 2018
|
31 |
171,016 |
AMRN, APEN, BSTC, BDSI
|
RESTATEMENT
|
11/28/2018 |
000156761918007015 |
|
Q2 2018
|
25 |
164,570 |
BSTC, CTIC, APEN, AMRN
|
13F-HR
|
8/14/2018 |
000156761918000669 |
|
Q1 2018
|
30 |
186,623 |
BSTC, CTIC, AMRN, VNDA
|
13F-HR
|
5/14/2018 |
000114036118023316 |
|
Q4 2017
|
27 |
166,847 |
VIVEVE MEDICAL INC, BSTC, APEN, VNDA
|
13F-HR
|
2/13/2018 |
000114036118007210 |
|
Q3 2017
|
22 |
169,648 |
VIVEVE MEDICAL INC, ENTA, PCRX, SCTL
|
13F-HR
|
11/13/2017 |
000114036117042192 |
|
Q2 2017
|
27 |
185,191 |
Viveve Medical, Inc, ENTA, Novelion Therapeutics, Inc., SCTL
|
13F-HR
|
8/14/2017 |
000114036117031650 |
|
Q1 2017
|
21 |
177,452 |
SCTL, Viveve Medical, Inc, Novelion Therapeutics, Inc., SCLN
|
13F-HR
|
5/12/2017 |
000114036117020108 |
|
Q4 2016
|
23 |
167,888 |
SCTL, Aegerion Pharmaceuticals, Inc., ALR, SCLN
|
13F-HR
|
2/10/2017 |
000114036117005766 |
|
Q3 2016
|
17 |
122,629 |
TBRA, Viveve Medical, Inc, Aegerion Pharmaceuticals, Inc., ALR
|
13F-HR
|
11/14/2016 |
000114036116086160 |
|
Q2 2016
|
23 |
97,537 |
SCLN, Viveve Medical, Inc, Aegerion Pharmaceuticals, Inc. (NOTES), VNDA
|
RESTATEMENT
|
8/11/2016 |
000114036116075782 |
|
Q1 2016
|
19 |
84,794 |
SCLN, VNDA, VCEL, PAIN THERAPEUTICS INC
|
13F-HR
|
5/11/2016 |
000114036116064477 |
|
Q4 2015
|
13 |
85,361 |
VNDA, CTIC, SCLN, TBRA
|
13F-HR
|
2/11/2016 |
000114036116051710 |